Stock listing
Tradegate:10V Immunic, Inc. Aktie
German listing (Tradegate) of Immunic, Inc. · home listing NASDAQ:IMUX
Follow Immunic, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:IMUX
$6.99 USD -0.53 (-7.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IMUX
- Day range
- $6.97 – $7.56 USDNov 20, 2026
- Volume
- 295,908 sharesNov 20, 2026
- Market cap
- $95.37M USDAt the close on Nov 20, 2026 · price × 13.64M shares outstanding
- 52-week range
- $5.06 – $17.43 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.22M USDMedian day 316,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IMUX · Home | $6.99 USD | -0.53 (-7.0%) | 295,908 | $7.31 | $7.56 | $6.97 | $7.52 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMUX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.99 | -0.53 | -7.0% | $7.31 | $7.56 | $6.97 | 295,908 | |
| $7.52 | +0.19 | +2.6% | $7.32 | $7.74 | $7.32 | 174,721 | |
| $7.33 | +0.10 | +1.4% | $7.26 | $7.475 | $7.06 | 141,197 | |
| $7.23 | -0.29 | -3.9% | $7.51 | $7.828 | $7.21 | 171,069 | |
| $7.52 | -0.27 | -3.5% | $7.87 | $7.87 | $7.52 | 105,144 | |
| $7.79 | -0.33 | -4.1% | $7.95 | $8.106 | $7.50 | 218,938 | |
| $8.12 | +0.08 | +1.0% | $8.20 | $8.42 | $8.08 | 156,857 | |
| $8.04 | +0.08 | +1.0% | $7.89 | $8.14 | $7.73 | 198,112 | |
| $7.96 | +0.21 | +2.7% | $7.885 | $8.22 | $7.553 | 260,223 | |
| $7.75 | +0.43 | +5.9% | $7.40 | $7.88 | $7.34 | 179,666 | |
| $7.32 | -0.62 | -7.8% | $7.97 | $8.065 | $7.21 | 263,038 | |
| $7.94 | +0.34 | +4.5% | $7.78 | $8.00 | $7.49 | 175,684 | |
| $7.60 | +0.26 | +3.5% | $7.38 | $7.87 | $7.35 | 166,969 | |
| $7.34 | -0.17 | -2.3% | $7.68 | $7.85 | $7.16 | 276,573 | |
| $7.51 | -0.285 | -3.7% | $7.70 | $7.78 | $7.37 | 244,096 | |
| $7.795 | -0.185 | -2.3% | $7.99 | $8.22 | $7.60 | 201,540 | |
| $7.98 | +0.37 | +4.9% | $7.60 | $8.196 | $7.56 | 258,164 | |
| $7.61 | +0.33 | +4.5% | $7.32 | $7.73 | $7.31 | 356,175 | |
| $7.28 | -0.13 | -1.8% | $7.36 | $7.505 | $7.06 | 432,286 | |
| $7.41 | +0.19 | +2.6% | $7.41 | $7.44 | $6.995 | 367,126 | |
| $7.22 | -0.26 | -3.5% | $7.50 | $7.70 | $7.16 | 473,400 | |
| $7.48 | +0.07 | +0.9% | $7.44 | $7.85 | $7.41 | 329,800 | |
| $7.41 | +0.42 | +6.0% | $6.99 | $7.64 | $6.95 | 429,600 | |
| $6.99 | +0.02 | +0.3% | $6.97 | $7.285 | $6.81 | 319,800 | |
| $6.97 | -0.13 | -1.8% | $7.10 | $7.92 | $6.80 | 366,200 | |
| $7.10 | +0.44 | +6.6% | $6.64 | $7.14 | $6.59 | 285,100 | |
| $6.66 | -0.23 | -3.3% | $6.78 | $7.035 | $6.35 | 438,000 | |
| $6.89 | -1.06 | -13.3% | $7.96 | $8.14 | $6.825 | 572,800 | |
| $7.95 | -0.24 | -2.9% | $8.19 | $8.444 | $7.92 | 152,100 | |
| $8.19 | +0.63 | +8.3% | $7.63 | $8.60 | $7.47 | 510,900 | |
| $7.56 | -0.07 | -0.9% | $7.65 | $7.65 | $7.25 | 588,800 | |
| $7.63 | -0.19 | -2.4% | $7.80 | $7.899 | $7.49 | 381,200 | |
| $7.82 | -0.25 | -3.1% | $8.13 | $8.17 | $7.77 | 347,800 | |
| $8.07 | +0.11 | +1.4% | $8.00 | $8.17 | $7.70 | 490,200 | |
| $7.96 | -0.68 | -7.9% | $8.69 | $8.87 | $7.755 | 723,000 | |
| $8.64 | -0.66 | -7.1% | $9.30 | $9.467 | $8.60 | 557,700 | |
| $9.30 | +0.39 | +4.4% | $9.00 | $9.44 | $8.74 | 448,500 | |
| $8.91 | -0.60 | -6.3% | $9.60 | $9.63 | $8.87 | 435,000 | |
| $9.51 | +0.165 | +1.8% | $9.32 | $9.935 | $9.09 | 660,400 | |
| $9.345 | +0.025 | +0.3% | $9.42 | $9.50 | $9.12 | 316,600 | |
| $9.32 | -0.05 | -0.5% | $9.32 | $9.535 | $9.09 | 448,400 | |
| $9.37 | -1.47 | -13.6% | $10.85 | $11.12 | $9.36 | 660,600 | |
| $10.84 | +0.01 | +0.1% | $10.95 | $11.28 | $10.76 | 430,500 | |
| $10.83 | +0.21 | +2.0% | $10.86 | $11.07 | $10.47 | 468,600 | |
| $10.62 | +0.27 | +2.6% | $10.30 | $10.74 | $10.21 | 403,600 | |
| $10.35 | +0.23 | +2.3% | $10.38 | $10.50 | $10.10 | 578,900 | |
| $10.12 | -0.25 | -2.4% | $10.50 | $10.63 | $10.03 | 229,300 | |
| $10.37 | -0.86 | -7.7% | $11.19 | $11.27 | $10.30 | 287,300 | |
| $11.23 | -0.19 | -1.7% | $11.43 | $11.46 | $11.04 | 251,400 | |
| $11.42 | -0.42 | -3.5% | $11.93 | $11.95 | $11.24 | 332,700 | |
| $11.84 | -0.35 | -2.9% | $12.05 | $12.32 | $11.73 | 295,100 | |
| $12.19 | -0.55 | -4.3% | $12.72 | $12.99 | $11.99 | 352,800 | |
| $12.74 | -0.37 | -2.8% | $12.93 | $13.28 | $12.35 | 405,000 | |
| $13.11 | +0.35 | +2.7% | $12.77 | $13.17 | $12.44 | 420,900 | |
| $12.76 | -1.48 | -10.4% | $14.24 | $14.92 | $11.56 | 841,600 | |
| $14.24 | -0.34 | -2.3% | $14.70 | $15.22 | $14.10 | 225,100 | |
| $14.58 | -1.22 | -7.7% | $16.05 | $16.10 | $14.58 | 229,200 | |
| $15.80 | +0.40 | +2.6% | $15.39 | $16.00 | $15.19 | 124,800 | |
| $15.40 | -0.90 | -5.5% | $16.21 | $16.30 | $15.00 | 357,900 | |
| $16.30 | -0.19 | -1.2% | $16.49 | $16.70 | $16.10 | 162,900 | |
| $16.49 | +0.07 | +0.4% | $16.34 | $16.66 | $15.80 | 240,200 | |
| $16.42 | -0.04 | -0.2% | $16.50 | $17.18 | $16.15 | 231,100 | |
| $16.46 | -0.04 | -0.2% | $16.48 | $16.83 | $16.06 | 140,100 | |
| $16.50 | +0.40 | +2.5% | $16.22 | $16.83 | $16.20 | 147,700 | |
| $16.10 | -0.35 | -2.1% | $16.39 | $16.67 | $15.92 | 200,600 |
Splits
2 splits since 2019 · NASDAQ:IMUX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-40 | Consolidation |
- Ticker
- Tradegate:10V
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Tradegate
- Currency
- EUR
What changed lately
Latest news release · Nov 13, 2026
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · Nov 5, 2026
Investor Day (November 2026)
Investor day · 56 slides
Latest news
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 13, 2026
Closed $7.52 (-3.5%) on Nov 13, 2026
Immunic to Participate in Investor Conferences in November
Nov 2, 2026
Closed $7.34 (-2.3%) on Nov 2, 2026
Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
Oct 29, 2026
Closed $7.80 (-2.3%) on Oct 29, 2026
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Oct 21, 2026
Closed $7.48 (+0.9%) on Oct 21, 2026
Immunic Appoints Jaa Roberson as Chief People Officer
Oct 19, 2026
Closed $6.99 (+0.3%) on Oct 19, 2026
Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 13, 2026
Closed $6.89 (-13.3%) on Oct 13, 2026
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Oct 7, 2026
Closed $7.63 (-2.4%) on Oct 7, 2026
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
Sep 2, 2026
Closed $14.24 (-2.3%) on Sep 2, 2026
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
Sep 1, 2026
Closed $14.58 (-7.7%) on Sep 1, 2026
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 11, 2026
Closed $14.10 (0.0%) on Aug 11, 2026
Immunic, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 32 in the last 12 months · 207 in all · newest Nov 13, 2026 · oldest 2019
- Calls
- 13 calls with a replay · 13 with a transcript · latest Nov 7, 2024
- Decks
- 78 decks · latest Nov 5, 2026
Where Immunic, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IMUX · Home listing | NASDAQ | United States | USD |
| BOATS:IMUX | BOATS | United States | USD |
| Frankfurt:10V | Frankfurt | Germany | EUR |
| gettex:10V | gettex | Germany | EUR |
| LS Exchange:A428WY | LS Exchange | Germany | EUR |
| Tradegate:10V · This page | Tradegate | Germany | EUR |
| Lang & Schwarz:A428WY | Lang & Schwarz | Germany | EUR |
| Munich:10V | Munich | Germany | EUR |
Valuation
Price/book 0.9× against a median of 3.2×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$36.09M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.51
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Immunic, Inc. · NASDAQ:IMUX | US$95.37M | −US$36.09M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.51 |
| Unicycive Therapeutics, Inc. · NASDAQ:UNCY | US$97.77M | US$39.32M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 1.09 |
| NovaBridge Biosciences · NASDAQ:NBP | US$96.28M | US$68.37M | n/a | n/a | n/a | 3.2× | n/a | 0.0× | 1.37 |
| Wuhan YZY Biopharma Co., Ltd. Class H · HKEX:2496 | US$96.16M | US$105.5M | n/a | 7.9× | n/a | n/a | −53.2% | n/a | n/a |
| PDS Biotechnology Corporation · NASDAQ:PDSB | US$95.39M | US$80.15M | n/a | n/a | n/a | 7.1× | n/a | 0.0× | 2.04 |
| NRX Pharmaceuticals, Inc. · NASDAQ:NRXP | US$95.31M | US$76.46M | n/a | 17.7× | n/a | n/a | −458.5% | n/a | 2.23 |
| Allergy Therapeutics plc · LSE:AGY | US$95.27M | US$117.1M | n/a | 1.6× | n/a | 17.1× | −72.9% | 6.3× | n/a |
| Voyager Therapeutics, Inc. · NASDAQ:VYGR | US$95.21M | −US$11.60M | n/a | −0.5× | n/a | 0.7× | −416.3% | 0.0× | 1.45 |
| Outlook Therapeutics, Inc. · NASDAQ:OTLK | US$94.94M | US$83.70M | n/a | n/a | n/a | n/a | n/a | n/a | 1.10 |
| Molecular Partners AG · SIX:MOLN | US$93.53M | −US$4.92M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Sunhawk Vision Biotech, Inc. · TPEX:7759 | US$93.06M | US$82.44M | n/a | n/a | n/a | 7.3× | n/a | 0.0× | n/a |
| Median of the others | US$95.29M | US$78.30M | 4.8× | 3.2× | −244.6% | 0.0× | 1.41 |
Forecasts
13 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 42.64 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.60 · 12 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Erik Lundgren | Chief Executive Officer, Director |
| Glenn Whaley | Chief Financial Officer |
| Jason Tardio | President and Chief Operating Officer |
| Inderpal Singh | General Counsel |
| Jessica Breu | Vice President Investor Relations and Communications |
| Chitrang Davé | Chief Data and Digital Officer |
| Hella Kohlhof | Co-Founder, Chief Scientific Officer |
| Jaa Roberson | Chief People Officer |
| Michael A. Panzara | Chief Medical Officer |
| Patrick Walsh | Chief Business Officer |
| Werner Gladdines | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Michael W. Bonney | Chair |
| Barclay Buck Phillips | Independent Director |
| Elena Ridloff | Independent Director |
| Erik Lundgren | Chief Executive Officer, Director |
| Jon Congleton | Independent Director |
| Jörg Neermann | Independent Director |
| Richard Rudick | Independent Director |
| Simona Skerjanec | Independent Director |
| Thor Nagel | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Immunic (NASDAQ:IMUX) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 8:00 AM ET | Replay |
| Immunic (NASDAQ:IMUX) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:00 AM ET | Replay |
| Immunic (NASDAQ:IMUX) Q1 2024 Earnings Call | Wed, May 08, 2024 · 8:00 AM ET | Replay |
| Immunic (NASDAQ:IMUX) Q4 2023 Earnings Call | Thu, Feb 22, 2024 · 8:00 AM ET | Replay |
| Immunic (NASDAQ:IMUX) Q3 2023 Earnings Call | Tue, Nov 14, 2023 · 8:00 AM ET | Replay |
| Immunic (NASDAQ:IMUX) Q2 2023 Earnings Call | Thu, Aug 03, 2023 · 8:00 AM ET | Replay |
| Immunic (NASDAQ:IMUX) Q1 2023 Earnings Call | Thu, May 11, 2023 · 8:00 AM ET | Replay |
| Immunic (NASDAQ:IMUX) Q4 2022 Earnings Call | Thu, Feb 23, 2023 · 8:00 AM ET | Replay |
| Immunic (NASDAQ:IMUX) Q3 2022 Earnings Call | Thu, Nov 03, 2022 · 8:00 AM ET | Replay |
| Immunic (NASDAQ:IMUX) Q2 2022 Earnings Call | Thu, Aug 04, 2022 · 8:00 AM ET | Replay |
All 13 calls
| Call | When | Status |
|---|---|---|
| Immunic (NASDAQ:IMUX) Q1 2022 Earnings Call | Tue, May 10, 2022 · 8:00 AM ET | Replay |
| Immunic (NASDAQ:IMUX) Q4 2021 Earnings Call | Thu, Feb 24, 2022 · 8:00 AM ET | Replay |
| Immunic (NASDAQ:IMUX) Q3 2021 Earnings Call | Thu, Nov 04, 2021 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · Before open | −3.5% |
| Q2 2026 | Aug 11, 2026 · Before open | 0.0% |
| Q1 2026 | May 13, 2026 · Before open | +8.8% |
| Q4 2025 | Feb 26, 2026 | +12.1% |
| Q3 2025 | Nov 13, 2025 · Before open | −6.2% |
| Q2 2025 | Aug 7, 2025 · Before open | −7.9% |
| Q1 2025 | May 15, 2025 | −1.6% |
| Q4 2024 | Mar 31, 2025 · Before open | −9.2% |
| Q3 2024 | Nov 7, 2024 · Before open | 0.0% |
| Q2 2024 | Aug 8, 2024 · Before open | +14.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | −8.0% |
| Q4 2023 | Feb 22, 2024 · Before open | −4.7% |
| Q3 2023 | Nov 14, 2023 · Before open | +2.2% |
| Q2 2023 | Aug 3, 2023 · Before open | −1.4% |
| Q1 2023 | May 11, 2023 · Before open | +1.7% |
| Q4 2022 | Feb 23, 2023 · Before open | +4.2% |
| Q3 2022 | Nov 3, 2022 · Before open | −7.6% |
| Q2 2022 | Aug 4, 2022 · Before open | +23.1% |
| Q1 2022 | May 10, 2022 · Before open | +5.4% |
| Q4 2021 | Feb 24, 2022 · Before open | −9.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (November 2026) | Investor day | 56 slides | Nov 5, 2026 |
| Investor Presentation (November 2026) | Investor deck | 47 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 40 slides | October 2026 |
| Investor Day (September 2026) | Investor day | 58 slides | Sep 9, 2026 |
| Investor Presentation (September 2026) | Investor deck | 35 slides | September 2026 |
| Investor Presentation (July 2026) | Investor deck | 35 slides | Jul 14, 2026 |
| EFMC-ACSMEDI MedChem Frontiers 2026 | Conference | 18 slides | Jun 25, 2026 |
| UEG Week Berlin 2025 | Conference | 11 slides | Oct 6, 2025 |
| 41st Congress of ECTRIMS 2025 | Conference | 13 slides | Sep 25, 2025 |
| Investor Presentation (August 2025) | Investor deck | 72 slides | Aug 7, 2025 |
All 78 decks
Financings
| Raise | Date |
|---|---|
| Private placement of pre-funded warrants and warrants Closed: US$200M raised · US$0.873 a share · Warrants at US$0.873 · Leerink Partners +6 Dealers: Leerink Partners (lead), Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities, Brookline Capital Markets Buyers: BVF Partners L.P. (led the financing); Aberdeen Investments; Avidity Partners; Coastlands Capital; EcoR1 Capital; Janus Henderson Investors; OrbiMed; RA Capital Management; TCGX; Trails Edge Capital Partners; Vivo Capital; Woodline Partners LP Use of proceeds: To fund clinical trials and operations and for general corporate purposes | Feb 17, 2026 |
| Public offering of pre-funded warrants, Series A warrants and Series B warrants Closed: US$65M raised · US$0.7499 a share · Series A Warrants exercisable until December 31, 2025; Series B Warrants exercisable… · Leerink Partners +3 Dealers: Leerink Partners (lead), B. Riley Securities, Brookline Capital Markets, a division of Arcadia Securities, LLC, William Blair & Company, L.L.C. Buyers: BVF Partners (co-led the financing); Coastlands Capital (co-led the financing); Aberdeen Investments; Adage Capital Partners LP; Janus Henderson Investors Use of proceeds: Fund clinical trials and operations and general corporate purposes | Jun 3, 2025 |
| Registered direct offering of shares of common stock Closed: US$5.1M raised · US$0.9 a share · Titan Partners Group, a division of American Capital Partners Dealers: Titan Partners Group, a division of American Capital Partners (lead) Buyers: Aberdeen Investments Use of proceeds: Fund clinical trials and operations and other general corporate purposes | Apr 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as VITAL THERAPIES INC. Priced at US$12.00 a share on Apr 16, 2014.
- Price
- US$12.00 a share
- Shares offered
- 4,500,000 shares of common stock
- Offering size
- US$54 million
- Underwriters
- BofA Merrill Lynch, Credit Suisse, William Blair, Canaccord Genuity · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 22, 2013 |
| Filed publicly | Oct 11, 2013 |
| Amended 7 times | Newest Apr 9, 2014 |
| Shares registered with an exchange | Nov 15, 2013 |
| Declared effective by the SEC | Apr 16, 2014 |
| Final prospectus, with the price | Apr 17, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 17, 2014 |
| EFFECT · Notice that a registration is effective | Apr 16, 2014 |
| FWP · Free writing prospectus | Apr 16, 2014 |
| CORRESP · Letter to the SEC | Apr 14, 2014 |
| CORRESP · Letter to the SEC | Apr 14, 2014 |
| S-1/A · Registration statement, amended | Apr 9, 2014 |
| FWP · Free writing prospectus | Apr 9, 2014 |
| CORRESP · Letter to the SEC | Apr 8, 2014 |
| UPLOAD · Letter from the SEC | Apr 7, 2014 |
| S-1/A · Registration statement, amended | Apr 7, 2014 |
All 35 filings
Open IPO · From the cover of the final prospectus (424B4) filed Apr 17, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.00K |
| Cost of revenue | 168.0K | 134.0K | 111.0K | 77.0K | 85.0K | 39.0K | 50.0K | 15.0K | 998.0K | 206 |
| Gross profit | -168.0K | -134.0K | -111.0K | -77.0K | -85.0K | -39.0K | -50.0K | -15.0K | -998.0K | 5.79K |
| Research and development | 82.0M | 80.0M | 83.2M | 71.3M | 61.1M | 38.6M | 22.5M | 9.60M | 39.3M | 30.0M |
| Selling, general and administrative | 21.2M | 18.0M | 16.0M | 15.3M | 13.3M | 10.3M | 14.5M | 13.6M | 13.3M | 11.2M |
| Operating income | -103.2M | -98.1M | -99.2M | -119.5M | -91.7M | -49.0M | -37.0M | -12.0M | -52.7M | -41.3M |
| Depreciation and amortization | 168.0K | 134.0K | 111.0K | 77.0K | 85.0K | 39.0K | 50.0K | 15.0K | 998.0K | 1.81M |
| EBITDA | -103.1M | -97.9M | -99.1M | -119.4M | -91.6M | -48.9M | -37.0M | -12.0M | -51.7M | -39.5M |
| Interest expense | 1.04M | 85.0K | 58.0K | 107.0K | 0 | 0 | 0 | |||
| Income before tax | -97.2M | -100.5M | -93.6M | -120.4M | -92.9M | -44.0M | -34.9M | -41.5M | -52.1M | -41.0M |
| Income tax | 0 | -100.5M | 33.9M | -151.0K | -58.0K | -107.0K | 549.0K | -577.0K | -1.81M | |
| Net income | -97.2M | -100.5M | -93.6M | -120.4M | -92.9M | -44.0M | -34.9M | -11.5M | -52.1M | -41.0M |
| Earnings per share, basic | -0.62 | -1.00 | -2.11 | -3.78 | -3.93 | -2.81 | -4.52 | -13.63 | -1.31 | -1.31 |
| Earnings per share, diluted | -0.62 | -1.00 | -2.11 | -3.78 | -3.93 | -2.81 | -4.52 | -13.63 | -1.31 | -1.31 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 15.5M | 35.7M | 46.7M | 106.7M | 86.9M | 127.5M | 29.4M | 13.1M | 56.9M | 60.0M |
| Short-term investments | 0 | 9.63M | 0 | 0 | 0 | |||||
| Receivables | 4.12M | 684.0K | 703.0K | 296.0K | 2.15M | 295.0K | 408.0K | 191.0K | 541.5K | |
| Inventory | 5.61M | -2.15M | 3.42M | -408.0K | -191.0K | 0 | 0 | |||
| Current assets | 22.9M | 39.3M | 52.5M | 125.9M | 105.0M | 133.7M | 32.2M | 13.3M | 58.1M | 61.5M |
| Property, plant and equipment | 608.0K | 545.0K | 466.0K | 294.0K | 152.0K | 203.0K | 80.0K | 40.0K | 2.15M | 2.50M |
| Goodwill | 0 | 33.0M | 33.0M | 33.0M | 0 | 0 | 0 | |||
| Total assets | 24.1M | 40.9M | 54.3M | 127.8M | 139.1M | 167.9M | 66.0M | 13.4M | 60.4M | 64.0M |
| Accounts payable | 10.1M | 7.85M | 5.10M | 4.28M | 3.75M | 3.70M | 2.42M | 1.40M | 1.05M | 780.0K |
| Current liabilities | 30.6M | 22.2M | 24.7M | 13.1M | 11.4M | 8.40M | 7.07M | 1.92M | 10.3M | 5.48M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 684.0K | 1.00M | 1.33M | 1.56M | 992.0K | 976.0K | 520.0K | 37.2M | ||
| Total liabilities | 30.7M | 22.4M | 25.4M | 14.1M | 12.0M | 9.08M | 7.59M | 1.92M | 10.3M | 5.58M |
| Shareholders' equity | -6.67M | 18.4M | 28.9M | 113.7M | 127.1M | 158.8M | 58.4M | -25.7M | -13.3M | 58.4M |
| Shares outstanding | 15.9M | 90.2M | 45.2M | 39.3M | 26.3M | 21.2M | 10.7M | 847.0K | 42.4M | 32.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -85.8M | -84.8M | -70.8M | -65.1M | -83.2M | -46.1M | -28.5M | -9.74M | -40.4M | -35.8M |
| Capital spending | -161.0K | -264.0K | -334.0K | -112.0K | -67.0K | -146.0K | -55.0K | -32.0K | -685.0K | -556.0K |
| Free cash flow | -86.0M | -85.0M | -71.2M | -65.3M | -83.3M | -46.3M | -28.6M | -9.77M | -41.1M | -36.3M |
| Cash from investing | -161.0K | -264.0K | 9.46M | -9.74M | -67.0K | -146.0K | 10.5M | -32.0K | -678.0K | -21.0K |
| Cash from financing | 65.6M | 74.5M | 1.03M | 95.8M | 42.8M | 144.4M | 34.9M | 19.3M | 38.0M | 12.4M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 182.0K | 77.0K | 129.0K | 182.0K | 92.0K | 144.4M | 34.9M | 4.00K | 38.0M | 12.4M |
| Change in cash | -20.2M | -11.0M | -60.1M | 19.9M | -40.6M | 98.1M | 16.3M | 8.57M | -3.09M | -23.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 2, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Oct 1, 2026 | Offer document | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
All 837 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 11, 2026 | Management or board change | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 12, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 6, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 1, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | May 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 28, 2026 | Current report | SEC |
| 8-K · Current report | May 27, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | May 19, 2026 | Insider trade | SEC |
| 8-K · Current report | May 19, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 6, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | May 5, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 1, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Apr 30, 2026 | Offer document | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 28, 2026 | Management or board change | SEC |
| 8-K · Current report | Apr 23, 2026 | Current report | SEC |
| 10-K/A · Annual report, amended | Apr 22, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 14, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Apr 10, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Apr 9, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 6, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 2, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 1, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Mar 31, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 31, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 4, 2026 | Big-stake notice | SEC |
| D | Mar 4, 2026 | Other filings | SEC |
| DEF 14A · Proxy statement | Mar 2, 2026 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Feb 27, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 27, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 24, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 24, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 20, 2026 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Feb 20, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 19, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 13, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 6, 2026 | Current report | SEC |
| 8-K · Current report | Jan 5, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 25, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 27, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 8, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 11, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 27, 2025 | Current report | SEC |
| 4/A · Change in ownership, amended | Jun 20, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 20, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 20, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 20, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 8-K · Current report | May 30, 2025 | Material contract | SEC |
| 424B5 · Prospectus | May 30, 2025 | Offer document | SEC |
| 424B5 · Prospectus | May 28, 2025 | Offer document | SEC |
| 8-K · Current report | May 28, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 30, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2025 | Meeting notice | SEC |
| 424B5 · Prospectus | Apr 9, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 9, 2025 | Material contract | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 20, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 8-K · Current report | Dec 18, 2024 | Management or board change | SEC |
| 4/A · Change in ownership, amended | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 22, 2024 | Current report | SEC |
| 8-K · Current report | Sep 10, 2024 | Current report | SEC |
| 8-K · Current report | Sep 3, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 24, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 9, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jul 2, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 12, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 10, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 29, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | May 24, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 1, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Apr 30, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 26, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 8, 2024 | Meeting outcome | SEC |
Cap table
Built by 6ix from Immunic, Inc.’s releases · as of Feb 17, 2026
- Common shares
- 13,644,467
- Fully diluted
- 13,644,467
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 13,644,467 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.87 · expiry not stated |
| Warrants · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 13,644,467 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Mark N Lampert Other companies: Kymera Therapeutics, Inc. (Director · Since at least Jan 11, 2023); Olema Pharmaceuticals, Inc. (Director · Since at least Jun 10, 2022); MoonLake Immunotherapeutics (Director · Since at least Apr 5, 2022); Rain Oncology Inc (Director · Nov 8, 2022 – Jan 25, 2024 · Past); CTi Biopharma Corp (Director · Aug 9, 2022 – Jun 26, 2023 · Past) | Director · Since at least Feb 17, 2026 |
| Elena Ridloff Other companies: Sionna Therapeutics, Inc. (CFO and CBO · Since at least Feb 6, 2025); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Kronos Bio Inc (Director · Since at least Oct 8, 2020); ACADIA Pharmaceuticals Inc. (EVP and CFO · Jan 6, 2021 – Apr 29, 2021 · Past) | Director · Since at least Aug 6, 2026 |
| Muneer A Satter Other companies: Annexon, Inc. (Director · Since at least Jul 23, 2020); Rein Therapeutics, Inc. (See Remarks, Director · Jun 8, 2020 – Jan 8, 2021 · Past); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Jun 18, 2019 · Past); Akebia Therapeutics, Inc. (Director · Mar 19, 2014 – Jun 14, 2018 · Past) | Director · Apr 16, 2014 – Sep 13, 2018 · Past |
| Tamar D Howson Other companies: Cue Biopharma, Inc. (Director · Sep 17, 2020 – Jan 3, 2023 · Past); Lite Strategy, Inc. (Director · Jul 1, 2019 – Sep 29, 2023 · Past); VivoSim Labs, Inc. (Director · Jul 26, 2018 – Jul 26, 2018 · Past) | Director · Since at least Oct 11, 2019 |
| Jon Congleton Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); Mineralys Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Feb 9, 2023) | Director · Since at least Mar 27, 2026 |
| Jon Congleton Other companies: Mineralys Therapeutics, Inc. (Chief Executive Officer · Since at least Oct 2, 2026); Avalyn Pharma Inc. (Since at least Apr 6, 2026) | Independent Director · Since at least May 13, 2026 |
| Michael A. Panzara Other companies: LeonaBio, Inc. (Director · Since at least Mar 18, 2022); Wave Life Sciences Ltd. (See Remarks · Feb 1, 2021 – Jul 25, 2022 · Past) | Chief Medical Officer · Since at least Apr 24, 2026 |
| Randolph C Steer Other companies: Capstone Holding Corp. (President · Jan 17, 2011 – Jan 17, 2011 · Past); Bio-Techne Corp (Director · Oct 28, 2010 – Oct 26, 2023 · Past) | Director · Apr 16, 2014 – May 23, 2017 · Past |
| Simona Skerjanec Other companies: Atrium Therapeutics, Inc. (Director · Since at least Nov 10, 2025); Avidity Biosciences, Inc (Director · Since at least May 14, 2024) | Director · Since at least Jul 22, 2024 |
| Glenn Whaley Other companies: Pernix Therapeutics Holdings Inc (VP of Fin, PAO & Controller · Nov 29, 2017 – Aug 8, 2018 · Past) | Chief Financial Officer · Since at least Dec 1, 2019 |
All 30 people
| Person | Seat |
|---|---|
| Monika Maria Toernsen Other companies: Passage Bio, Inc. (Chief Commercial Officer · Jul 19, 2021 – Sep 15, 2022 · Past) | Director · Since at least Jul 5, 2022 |
| Aron Stern | Chief Administrative Officer · May 13, 2016 – Jul 1, 2018 · Past |
| Barclay A Phillips | Director · Since at least Jun 5, 2025 |
| Barclay Buck Phillips | Independent Director · Since at least Nov 5, 2026 |
| Chitrang Davé | Chief Data and Digital Officer · Since at least Sep 1, 2026 |
| Daniel Vitt | Director · Since at least Apr 12, 2019 |
| Duane Nash | Executive Chairman, Director · Since at least May 12, 2022 |
| Erik Lundgren | Chief Executive Officer, Director · Since at least May 22, 2026 |
| Hella Kohlhof | Co-Founder, Chief Scientific Officer · Since at least Oct 29, 2026 |
| Inderpal Singh | General Counsel · Since at least Nov 4, 2026 |
| Jaa Roberson | Chief People Officer · Since at least Oct 19, 2026 |
| Jason Tardio | President and Chief Operating Officer · Since at least Nov 2, 2026 |
| Jessica Breu | Vice President Investor Relations and Communications · Since at least Oct 29, 2026 |
| Jörg Neermann | Independent Director · Since at least Nov 5, 2026 |
| Manfred Groeppel | Chief Operating Officer · Apr 12, 2019 – Mar 1, 2021 · Past |
| Michael W. Bonney | Chair · Since at least Aug 11, 2026 |
| Patrick Walsh | Chief Business Officer · Since at least Nov 2, 2026 |
| Richard Rudick | Independent Director · Since at least Apr 26, 2023 |
| Thor Nagel | Director · Since at least May 13, 2026 |
| Werner Gladdines | Chief Development Officer · Since at least Jun 5, 2025 |
Log in to ask 6ix AI your own questions about Immunic, Inc.